Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide

Journal of Endocrinology

Volumn 176, Issue 1, 2003, Pages 133-141

  Gault, V A ^a   Flatt, P R ^a   Harriott, P ^b   Mooney, M H ^a   Bailey, C J ^c   O'Harte, F P M ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CYCLIC AMP; DIPEPTIDYL PEPTIDASE IV; DIPROTIN A; FORSKOLIN; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE DEPENDENT INSULINOTROPHIC POLYPEPTIDE; HORMONE RECEPTOR; ISOBUTYLMETHYLXANTHINE; PENICILLIN G; SERINE; STREPTOMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; BLOOD GLUCOSE MONITORING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DEGRADATION; DRUG HYDROLYSIS; DRUG STABILITY; GENETIC TRANSFECTION; GLUCOSE BLOOD LEVEL; HORMONE ACTION; HORMONE RESPONSE; LUNG FIBROBLAST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE METABOLISM; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW;

ANIMALS; BLOOD GLUCOSE; CELLS, CULTURED; CRICETINAE; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; GASTRIC INHIBITORY POLYPEPTIDE; HALF-LIFE; HUMANS; INSULIN; MICE; MICE, TRANSGENIC; MUTAGENESIS, SITE-DIRECTED; OBESITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TRANSFECTION;

EID: 0037253460     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1760133     Document Type: Review

References (44)

1. Bailey CJ & Flatt PR 1982 Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. International Journal of Obesity 6 11-21.
2. Bailey CJ & Flatt PR 1995 Development of antidiabetic drugs. In Drugs, Diet and Disease: Mechanistic Approaches to Diabetes, pp 279-326. Eds C Ionnides & PR Flatt. London: Ellis Horwood.
3. Barrett AJ & Rawlings ND 1992 Oligopeptidases, and the emergence of the prolyl oligopeptidase family. Biological Chemistry Hoppe-Seyler 373 353-360.
4. Bray GA & York DA 1979 Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiological Reviews 59 719-809.
5. Brown JC, Dahl M, Kwauk S, McIntosh CHS, Otte SC & Pederson RA 1981 Actions of GIP. Peptides 2 (Suppl) 241-245.
6. Buchan MT, Polak JM, Capella C, Solcia E & Pearse AG 1978 Electroimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man. Histochemistry 56 37-44.
7. Burcelin R, Dolci W & Thorens B 1999 Long-lasting antidiabetic effects of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metabolism 48 252-258.
8. Burington RS 1973 Handbook of Mathematical Tables and Formulas. New York, NY: McGraw-Hill.
9. Creutzfeldt W 2001 The entero-insular axis in type 2 diabetes - incretins as therapeutic agents. Experimental Clinical Endocrinology and Diabetes 109 S288-S303.
10. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O & Holst JJ 1998 Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41 271-278.
11. Deacon CF, Danielsen P, Klarskov L, Olesen M & Holst JJ 2001 Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 50 1588-1597.
12. Eckel RH, Fujimoto WJ & Brunzell JD 1979 Gastric inhibitory polypeptide enhances lipoprotein lipase activity in cultured preadipocytes. Diabetes 28 1141-1142.
13. 2 in GIP stimulated insulin secretion. Journal of Biological Chemistry 276 23667-23673.
14. Elahi D, Meneilly GS, Minaker KL, Rowe JW & Andersen DK 1986 Regulation of hepatic glucose production by gastric inhibitory polypeptide in man. Proceedings of the Sixth International Conference on Gastrointestinal Hormones. Ottawa: National Research Council of Canadian Research Journals.
15. Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF & Andersen DK 1994 The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regulatory Peptides 51 63-74.
16. Fields GB & Noble RL 1990 Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. International Journal of Peptide and Protein Research 35 161-214.
17. Flatt PR & Bailey CJ 1981 Abnormal plasma glucose and insulin responses in heterozygous lean ob/+ mice. Diabetologia 20 573-577.
18. Gault VA, Parker JC, Harriott P, Flatt PR & O'Harte FPM 2002 Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. Journal of Endocrinology 175 525-533.
19. Gremlich S, Porret A, Hani EH, Cherif D, Vionnet N, Froguel P & Thorens B 1995 Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 44 1202-1208.
20. Heins J, Welker P, Schönlein C, Born I, Hartrodt B, Neubert K, Tsuru D & Barth A 1988 Mechanism of proline-specific proteinases: substrate-specificity of dipeptidyl peptidase IV from pig kidney and proline-specific endopeptidase from Flavobacterium meningosepticum. Biochimica et Biophysica Acta 954 161-169.
21. 2]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 51 656-661.
22. Holst JJ 1999 Glucagon-like peptide-1; a gastrointestinal hormone with pharmaceutical potential. Current Opinion in Medicinal Chemistry 6 1005-1017.
23. Kieffer TJ, McIntosh CHS & Pederson RA 1995 Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 3585-3596.
24. Knapper JM, Puddicombe SM, Morgan LM & Fletcher JM 1995 Investigations into the actions of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1(7-36)amide on lipoprotein lipase activity in explants of rat tissue. Journal of Nutrition 125 183-188.
25. Kühn-Wache K, Manhart S, Hoffmann T, Hinke SA, Gelling RW, Pederson RA, McIntosh CHS & Demuth H-U 2000 Analogs of glucose-dependent insulinotropic polypeptide with increased dipeptidyl peptidase IV resistance. Advances in Experimental Medicine and Biology 477 187-195.
26. Lodja Z 1979 Studies on dipeptidyl(amino)peptidase IV (glycyl-proline naphthylamidase). II. Blood vessels. Histochemistry 59 153-166.
27. Lu M, Wheeler MB, Leng X-H & Boyd AE 1993 The role of the free cytosolic calcium level in β-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide-1-(7-37). Endocrinology 132 94-100.
28. McClenaghan NH, Barnett CR, Ah-Sing E, Abdel-Wahab YHA, O'Harte FPM, Yoon T-W, Swanston-Flatt SK & Flatt PR 1996 Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 45 1132-1140.
29. Mentlein R 1999 Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regulatory Peptides 85 9-24.
30. Moens K, Heimberg H, Flamez D, Huypens P, Quartier E, Ling Z, Pipeleers D, Gremlich S, Thorens B & Schuit F 1996 Expression and functional activity of glucagon, glucagon-like peptide-1, and glucose-dependent insulinotropic polypeptide receptors in rat pancreatic islet cells. Diabetes 45 257-261.
31. Nauck MA, Bartels E, Ørskov C, Ebert R & Creutzfeldt W 1993 Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near physiological insulinotropic hormone and glucose concentrations. Journal of Clinical Endocrinology and Metabolism 76 912-917.
32. Oben J, Morgan L, Fletcher J & Marks V 1991 Effects of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1 (7-36) amide on fatty acid synthesis in explants of rat adipose tissue. Journal of Endocrinology 130 267-272.
33. O'Harte FPM, Gray AM & Flatt PR 1998a Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle. Journal of Endocrinology 156 237-243.
34. O'Harte FPM, Abdel-Wahab YHA, Conlon JM & Flatt PR 1998b Amino-terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells. Biochimica et Biophysica Acta 1425 319-327.
35. O'Harte FPM, Mooney MH & Flatt PR 1999 N-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity. Diabetes 48 758-765.
36. O'Harte FPM, Mooney MH, Kelly CMN & Hart PR 2000 Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide. Journal of Endocrinology 165 639-648.
37. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CHS & Demuth H-U 1998 Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47 1253-1258.
38. Pospisilik JA, Stafford SG, Demuth H-U, Brownsey P, Parkhouse W, Finegood DT, McIntosh CHS & Pederson RA 2002 Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 51 943-950.
39. Ritzel U, Leonhardt U, Ottleben M, Rühmann A, Eckart K, Speiss J & Ramadori G 1998 A synthetic glucagon-like peptide-1 analogue with improved plasma stability. Journal of Endocrinology, 159 93-102.
40. Shipp MA & Look AT 1993 Hematopoietic differentiation antigens that are membrane-associated enzymes. Blood 82 1052-1070.
41. Stevens JF 1971 Determination of glucose by an automatic analyser. Clinica Chimica Acta 32 199-201.
42. Usdin TB, Mezey E, Button DC, Brownstein MJ & Bonner TI 1993 Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133 2861-2870.
43. Widmann C, Bürki E, Dolci W & Thorens B 1993 Signal transduction by the cloned glucagon-like peptide-1 receptor: comparison with signalling by the endogenous receptors of β cell lines. Molecular Pharmacology 45 1029-1035.
44. Yip RG-C, Boylan MO, Kieffer TJ & Wolfe MM 1998 Functional GIP receptors are present on adipocytes. Endocrinology 139 4004-4007.